 Leverkusen, Germany, July 23, 2021 GLOBE NEWSWIRE -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F, and Medac Gesellschaft für klinische Spezialpräparate mbH. Medac, signed an exclusive license and supply agreement for the marketing of both Ameluz and BF-RhodoLED in Poland. The agreement has a term of 5 years commencing with the start of sales in Poland. 